What similarly acting projects are still unpartnered?

After a conference lacking the wow factor, biotech winners and losers emerge.

Early data suggest that PD-(L)1 x VEGF bispecifics might challenge Keytruda in triple-negative disease.

The small cap biotech Instil Bio tries to follow in Summit’s slipstream.

Akeso’s data look impressive, but perhaps not impressive enough to sustain Summit’s valuation.

It’s back to school for biotech, with a packed conference schedule.

The companies’ PD-(L)1 x VEGF bispecifics will clash in triple-negative breast cancer.

As the dust settles on ASCO the weekend’s immediate winners and losers emerge.

The PD-1 x VEGF bispecific apparently bests Keytruda, but questions remain.